ADMA Biologics Inc $ADMA Stock Holdings Lessened by Aberdeen Group plc
Aberdeen Group plc reduced its stake in ADMA Biologics Inc by 13.6% in the fourth quarter, selling over 150,000 shares but still maintaining a holding valued at about $17.58 million. Despite mixed analyst ratings, the consensus is a "Buy" with an average price target of $32.00. The company reported Q4 EPS of $0.20, meeting estimates, and revenues of $139.16 million, slightly below expectations.
ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman Investigating ADMA Investors with Losses Encouraged to Contact Hagens Berman
Hagens Berman is investigating ADMA Biologics after a short seller report by Culper Research accused the company of channel stuffing, an undisclosed related party distributor, and inflated revenue growth. The report claims ADMA's skyrocketing Days Sales Outstanding (DSO) indicates the company induced distributors to stock excess product through rebates and extended payment terms, leading to a 16% stock price drop. Hagens Berman is encouraging investors with losses to come forward as they investigate potential violations of federal securities laws.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ADMA Biologics, Inc. (ADMA) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into ADMA Biologics, Inc. (ADMA) following allegations of "channel stuffing" and undisclosed related party transactions by Culper Research. The report claims ADMA's reported growth is artificial, estimating a 3% revenue decline in 2025 without these practices, as opposed to the reported 20% growth. Following the report's publication, ADMA's stock price dropped by 16.63%.
ADMA Biologics extends selloff as Cantor downgrades after short report
NULL
Allspring Global Investments Holdings LLC Decreases Stock Position in ADMA Biologics Inc $ADMA
Allspring Global Investments Holdings LLC significantly reduced its stake in ADMA Biologics Inc by 68.3% in Q4, selling over 1 million shares. Despite this, other hedge funds showed mixed activity, with some increasing and some initiating new positions. Insider transactions included a sale by the COO and a purchase by a director, while analysts maintain a "Buy" rating with an average target price of $32.00 after the company met EPS expectations.
ADMA SEC Filings - Adma Biologics 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Adma Biologics (ADMA) SEC filings, including annual 10-K, quarterly 10-Q, material event 8-K, and insider trading Form 4 reports. It details recent insider transaction filings for ADMA's COO, CFO, and CEO, explaining share withholdings for tax obligations and stock option exercises. The platform offers AI-generated summaries and impact analysis for regulatory documents, enhancing understanding for investors.
Bronstein, Gewirtz & Grossman, LLC Is Investigating ADMA Biologics, Inc. (ADMA) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into ADMA Biologics, Inc. following a short report by Culper Research. The report alleges that ADMA's reported growth is a result of "channel stuffing" and undisclosed related-party distribution, claiming revenues actually declined in 2025. Following the report, ADMA's stock price fell significantly, and the firm is encouraging affected investors to join their investigation.
ADMA (ADMA) COO reports 20,362-share RSU tax withholding, holds 446,238 shares
ADMA Biologics COO and SVP, Compliance, Kaitlin M. Kestenberg-Messina had 20,362 shares of common stock withheld to cover taxes on vesting restricted stock units (RSUs) at a price of $9.11 per share. This was a mandatory tax withholding and not an open-market sale. Following this transaction, she directly holds 446,238 shares of ADMA common stock, which includes various blocks of unvested RSUs and shares from prior option exercises.
Stock Drop Alert: ADMA Biologics ($ADMA) Stock Plummets 29% after Channel Stuffing Claims Disclosed - Investors Notified of Securities Fraud Investigation
BFA Law is investigating ADMA Biologics (NASDAQ:ADMA) for potential securities fraud after the company's stock dropped 29%. This comes after Culper Research accused ADMA Biologics of "channel stuffing" to inflate its 2025 revenue growth, which they claim was actually a decline. Investors who purchased ADMA stock are encouraged to contact BFA Law for more information on potential legal options.
ADMA INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving ADMA Biologics, Inc.
Kirby McInerney LLP is investigating potential claims against ADMA Biologics, Inc. (NASDAQ:ADMA) following a report by Culper Research. The report, published on March 24, 2026, alleges "Channel Stuffing, an Undisclosed Related Party Distributor, and -3% Real Growth in 2025 vs. +20% Reported," causing ADMA's stock price to drop significantly. The law firm is encouraging investors who purchased ADMA securities to contact them to discuss their legal rights.
ADMA Biologics Investigated for Securities Fraud After Plunge
ADMA Biologics (NASDAQ:ADMA) is under investigation by Bleichmar Fonti & Auld LLP for potential securities fraud following a 29% stock drop. This investigation was triggered by a Culper Research report alleging the company used a "channel stuffing scheme" to inflate its 2025 revenue growth. Culper Research claims ADMA induced a distributor to overstock ASCENIV with rebates and extended payment terms, fabricating reported growth.
ADMA SEC Filings - Adma Biologics 10-K, 10-Q, 8-K Forms
This page provides access to Adma Biologics (ADMA) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event reports (8-K), and insider trading forms (Form 4), alongside AI-generated explanations. The content shows recent filings detailing insider trading activity by CEO Adam S. Grossman, Q3 2025 financial results ($134.224 million revenue, $36.428 million net income), and a material event report referencing the Q3 earnings press release.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
Pomerantz LLP is investigating potential securities fraud claims against ADMA Biologics, Inc. (NASDAQ: ADMA) following allegations of "channel stuffing" and undisclosed related party distribution by Culper Research, which led to a significant stock price drop. The investigation intensified after Cantor Fitzgerald downgraded ADMA, citing an inadequate response to these allegations, causing further declines in the company's stock value. Pomerantz LLP encourages affected investors to contact them to learn more about joining the class action.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ADMA Biologics, Inc. (ADMA) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into ADMA Biologics, Inc. (ADMA) following a short report by Culper Research. The report alleges that ADMA's reported growth is artificial, stemming from a channel stuffing scheme and an undisclosed related party distributor, claiming revenues actually declined in 2025 despite reported growth. Investors who purchased ADMA securities are encouraged to contact the firm to learn more and potentially join the investigation.
ADMA INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving ADMA Biologics, Inc.
Kirby McInerney LLP is investigating potential claims against ADMA Biologics, Inc. following a report by Culper Research on March 24, 2026. The report alleged that ADMA engaged in "channel stuffing" and used an undisclosed related-party distributor, leading to an overstatement of growth. This news caused ADMA's stock price to drop by approximately 17%.
Investor Notice: ADMA Biologics ($ADMA) Stock Dropped 29% After Culper Research Report Announcement - Investigation Pending
Bleichmar Fonti & Auld LLP (BFA Law) has launched an investigation into ADMA Biologics (NASDAQ:ADMA) for potential securities law violations. This comes after a Culper Research report alleged channel stuffing by ADMA in 2025, leading to a 29% stock drop. The report claims ADMA's reported 20% revenue growth was fabricated, masking an actual 3% decline.
ADMA Biologics Investigated for Securities Fraud After Stock Drop
BFA Law is investigating ADMA Biologics for alleged securities fraud after its stock plummeted 29%. This investigation follows claims by Culper Research of channel stuffing and the use of an undisclosed related party distributor, potentially violating federal securities laws. The case underscores the critical importance of transparency and accurate financial reporting for public companies.
ADMA Securities News: ADMA Biologics Investigated for Securities Fraud After Culper Research Report Revelation Sparks 29% Stock Drop
Bleichmar Fonti & Auld LLP is investigating ADMA Biologics (NASDAQ: ADMA) for potential securities fraud following a 29% stock drop. This investigation was sparked by a Culper Research report alleging that ADMA Biologics engaged in channel stuffing to falsely report 20% revenue growth in 2025, when true growth was purportedly -3%. Investors who purchased ADMA Biologics stock may have legal options.
ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman Investigating
ADMA Biologics, Inc. (ADMA) shares crashed over 16% after short seller Culper Research accused the company of channel stuffing, using undisclosed related party distributors, and inflating reported growth by extending payment terms to distributors. Hagens Berman, a national shareholders rights firm, is investigating whether ADMA violated federal securities laws, focusing on the company's financial statements and internal control over financial reporting. The investigation emphasizes ADMA's skyrocketing Days Sales Outstanding (DSO) and alleged misrepresentation of revenue growth.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ADMA Biologics, Inc. (ADMA) And Encourages Stockholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into ADMA Biologics, Inc. (ADMA) following allegations of channel stuffing and undisclosed related party distribution by Culper Research. The report claims ADMA's reported 20% growth in 2025 was ficticious, estimating a 3% decline without these practices, which led to a 16.63% drop in ADMA's stock. The firm is encouraging investors who purchased ADMA securities to contact them to assist with the investigation.
ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman Investigating
ADMA Biologics, Inc. (ADMA) shares plummeted over 16% following a report by short seller Culper Research alleging improper channel stuffing, an undisclosed related party distributor, and inflated revenue growth. The report claims ADMA manipulated its Days Sales Outstanding (DSO) by offering extended payment terms and rebates to distributors to stock excess product, thereby booking revenues for growth that didn't genuinely exist. National shareholders rights firm Hagens Berman is now investigating whether ADMA violated federal securities laws, urging affected investors and potential witnesses to come forward.
$ADMA Investor News: ADMA Biologics Faces Securities Fraud
BFA Law has announced an investigation into ADMA Biologics (NASDAQ:ADMA) for potential securities fraud. This follows a Culper Research report alleging the company engaged in channel stuffing to falsely boost its reported 2025 revenue growth. The revelations caused ADMA Biologics' stock to drop 29%, leading BFA Law to encourage affected investors to seek legal recourse.
$ADMA Investor News: ADMA Biologics Faces Securities Fraud
ADMA Biologics is under investigation for potential securities fraud by Bleichmar Fonti & Auld LLP after a report by Culper Research alleged channel stuffing to inflate its 2025 revenue. The report claims that instead of a reported 20% growth, the company would have seen a 3% decline without inducing distributors to overstock its flagship product, ASCENIV. This news led to a 29% drop in ADMA Biologics' stock price, and investors who suffered losses are encouraged to seek legal options.
ADMA Biologics (ADMA) soars 11.6% as firm denies short seller allegations
ADMA Biologics saw its stock price jump by 11.6% after the company publicly denied allegations made by a short seller. The firm's rebuttal to these claims led to a significant positive market reaction.
Bronstein, Gewirtz & Grossman, LLC Is Investigating ADMA Biologics, Inc. (ADMA) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into ADMA Biologics, Inc. (ADMA) following allegations of "channel stuffing" and an undisclosed related-party distributor, as detailed in a report by Culper Research. The report claims ADMA's reported revenue growth is fictitious, estimating a 3% decline in 2025 revenues without these practices, contrary to the reported 20% increase. After the report's publication, ADMA's stock price dropped by 16.63%.
ADMA Biologics Inc (NASDAQ:ADMA) Short Interest Update
ADMA Biologics (NASDAQ:ADMA) experienced a significant 35% growth in short interest during March, reaching 25.8 million shares, representing 11.3% of shares outstanding. Despite a company rebuttal against a short-seller report that caused an 11.6% stock jump, legal and sentiment risks persist due to ongoing securities-fraud investigations. Analyst ratings are split, with a consensus "Buy" and an average price target of $32.00, while insider transactions show mixed signals.
ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research
ADMA Biologics has issued a statement refuting allegations made by short seller Culper Research regarding its immune globulin products, ASCENIV and BIVIGAM. The company clarifies that demand for ASCENIV is growing, distributor inventory levels align with industry standards given the long production cycle, and ASCENIV's positioning as a late-line therapy for immune-compromised patients justifies its premium pricing. ADMA also asserts that its financial statements have received unqualified opinions from a Big Four accounting firm and that there have been no undisclosed related-party transactions.
ADMA Biologics (ADMA) counters Culper short report, cites record ASCENIV demand
ADMA Biologics has issued an 8-K filing to formally refute a short-seller report by Culper Research, which made allegations against ADMA's business practices and its immune globulin product, ASCENIV. The company states that demand for ASCENIV is at a record high and growing, and that its distributor stocking levels are in line with industry standards, countering claims of "channel stuffing." ADMA reiterates ASCENIV's FDA-approved indication as a late-line therapy for immune-compromised patients and provides details about its manufacturing approach and patent protection.
ADMA BIOLOGICS, INC. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
Kirby McInerney LLP is investigating potential securities fraud claims against ADMA Biologics, Inc. following a report by Culper Research. The report alleges "channel stuffing" and misleading growth figures, causing ADMA's stock price to drop by approximately 17%. The law firm is encouraging affected investors to contact them for more information regarding their rights.
ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman Investigating
Shares of ADMA Biologics, Inc. (ADMA) fell over 16% after short seller Culper Research accused the company of improper channel stuffing and concealing sales to an undisclosed related party. Hagens Berman is now investigating whether ADMA violated federal securities laws, prompted by Culper's report detailing a significant increase in days sales outstanding (DSO) and claims that ADMA manipulated revenue reporting. The investigation focuses on ADMA's financial statements and internal controls over financial reporting.
ADMA Biologics’ Shares React To Market Movements Amidst Share Buyback Plans
ADMA Biologics' shares rallied by 12.18% after positive market sentiment and FDA approvals, despite facing a 19% drop linked to a Cantour Fitzgerald downgrade. The company announced a $125 million accelerated share repurchase program and actively refuted short-seller claims. Amidst market turbulence, ADMA's strategic financial moves aim to restore investor confidence and highlight its intrinsic value.
ADMA Biologics Inc (ADMA Biologics) has issued an official statement regarding the recent report released by Culper Research
ADMA Biologics Inc. has released an official statement to refute a recent report by Culper Research, labeling its allegations as unfounded and misleading. The company firmly denies all false statements within the report. ADMA Biologics reaffirms its commitment to operational integrity and its responsibilities to shareholders and patients.
ADMA Biologics Inc recently responded to a short-selling report, firmly stating that the report presents a serious distortion and confusion regarding the actual efficacy and competitive position of its product Asceniv in the intravenous immunoglobulin (IVIG) market.
ADMA Biologics Inc. has issued a strong rebuttal to a recent short-selling report, asserting that the report misrepresents the actual efficacy and competitive standing of its IVIG product, Asceniv. The company claims the report fails to accurately reflect Asceniv's clinical value and market position.
ADMA BREAKING INVESTIGATION: BFA Law Launches Investigation into ADMA Biologics after Short Seller Report -- Investors Notified to Contact BFA Law
Bleichmar Fonti & Auld LLP (BFA Law) has initiated an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) following a short seller report by Culper Research. The report alleges that ADMA's reported 20% revenue growth in 2025 was a result of a "channel stuffing" scheme, and that actual growth was -3%. The news led to a significant drop in ADMA's stock price, and BFA Law is encouraging affected investors to contact them for potential legal options.
INVESTOR ALERT: Investigation of ADMA Biologics, Inc. (ADMA) Announced by Holzer & Holzer, LLC
Holzer & Holzer, LLC is investigating ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of federal securities laws following a report from Culper Research. The report alleges that ADMA's reported growth is a result of a "channel stuffing scheme and an undisclosed related party distributor," estimating a 3% revenue decline in 2025 without these tactics, contrary to the reported 20% increase. The investigation was prompted by a subsequent drop in ADMA's stock price.
Why Are Shares Of ADMA Biologics Falling Today?
ADMA Biologics shares are falling significantly after Cantor Fitzgerald downgraded the stock to Neutral following a short-seller report from Culper Research. The report alleges misrepresentation of financial results and operating metrics, which ADMA Biologics denies. The stock has seen a sharp decline this week and over the past three months, trading well below key moving averages and reaching a new 52-week low.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
Pomerantz LLP is investigating potential securities fraud claims against ADMA Biologics, Inc. ("ADMA") following a short report by Culper Research. The report alleges that ADMA's reported growth is a result of a "channel stuffing scheme" and an undisclosed related-party distributor, which supposedly inflated revenues. Following the report's publication, ADMA's stock price dropped significantly.
INVESTOR ALERT: Investigation of ADMA Biologics, Inc. (ADMA) Announced by Holzer & Holzer, LLC
Holzer & Holzer, LLC has announced an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) following allegations from Culper Research that the company's reported growth is a "fiction driven by a de facto channel stuffing scheme and an undisclosed related party distributor." The report claims ADMA's revenues would have declined by 3% in 2025 without these practices, in contrast to the reported 20% growth, leading to a drop in the company's stock price. Shareholders who experienced losses are encouraged to contact Holzer & Holzer to discuss their legal rights.
ADMA Biologics (ADMA) Downgraded to Neutral by Cantor Fitzgerald
Cantor Fitzgerald analyst Kristen Kluska downgraded ADMA Biologics (ADMA) from Overweight to Neutral, with no price target adjustment. This follows a previous Strong Buy rating and increased price target from Raymond James in May 2025. Despite the downgrade, the average one-year price target from three analysts implies a significant upside from its current price, and the consensus brokerage recommendation indicates an "Outperform" status.
Assessing ADMA Biologics (ADMA) Valuation After Fresh Analyst Upgrades And Strong Buy Sentiment
Analyst sentiment for ADMA Biologics (ADMA) has improved, leading to a consensus Strong Buy rating despite recent share price declines. The stock appears undervalued based on an estimated intrinsic value and analyst price targets, with one narrative suggesting a fair value of $20.93. However, a contrasting view based on market ratios indicates a richer price, with its P/E ratio exceeding industry averages, suggesting expectations are already priced in.
Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against ADMA Biologics, Inc.
Ademi LLP is investigating potential securities fraud claims against ADMA Biologics, Inc. (NASDAQ: ADMA). The investigation stems from alleged inaccurate statements made by ADMA regarding its financial statements, business operations, and prospects, specifically concerning revenue accounting. Shareholders who believe they have been affected are invited to join the investigation.
ADMA Biologics Under Scrutiny as Stock Shows Volatility in Recent Sessions
ADMA Biologics (ADMA) stock has declined by 14.21% recently, fueled by concerns over sluggish revenue growth, higher debt ratios, and increased competition in the biotech sector. Despite favorable short-term liquidity, analysts are cautious due to decreasing ROI metrics and broader economic pressures. The company faces the need for strategic recalibration to sustain growth amidst market volatility.
Short Seller Report Alleges ADMA Biologics Financial Misrepresentation
Culper Research has released a report alleging financial misrepresentation by ADMA Biologics, leading to a significant drop in ADMA's stock price. While the short seller holds a position against the company, ADMA Biologics denies the claims and reaffirms its commitment to transparency and SEC regulations. The company's stock is currently trading well below its moving averages and is in oversold territory, reflecting a challenging year.
ADMA Biologics (ADMA) Responds to Short Report, Shares Drop 17%
ADMA Biologics (ADMA) saw its shares drop 17% after Culper Research published a short report, which ADMA claims contains inaccurate information. The company, which specializes in plasma-derived biologics, is reviewing the assertions made in the report. Despite strong financial health and revenue growth, ADMA faces market skepticism, high volatility, and mixed insider activity, presenting a complex investment scenario.
ADMA Biologics Addresses Misleading Short-Seller Report
ADMA Biologics has responded to a short-seller report issued by Culper Research, calling its assertions speculative, false, and inaccurate. The company states it takes its reporting obligations seriously and is reviewing the claims despite their unreliable nature. Culper Research has disclosed a short position in ADMA.
ADMA stock drops 6% after Culper Research alleges channel stuffing
ADMA Biologics stock dropped 6% after Culper Research accused the company of channel stuffing and misleading investors about its product demand. Culper initiated a short position, citing inflated inventory, significant customer concentration, weak earnings, and executive departures as reasons behind its bearish stance.
Adma Biologics Shares Drop After Short Report
Adma Biologics' (ADMA) shares fell following a short report from Culper Research, which accused the company of "channel stuffing" and projected a revenue decline in 2025. Despite this, ADMA announced a capital return initiative including a $125 million share repurchase agreement and forecasted $635 million in revenue for 2026. The short report has triggered investor concern, contrasting with the company's recent positive financial reports and increased earnings estimates from other sources.
Culper Research Says We Are Short ADMA Biologics
Culper Research has announced that it is shorting ADMA Biologics. The information was distributed through Reuters and is noted as less than a minute read. The article mentions ADMA analysts and government bonds.
Adma Biologics stock hits 52-week low at 13.76 USD
ADMA Biologics stock has fallen to a 52-week low of $13.76, a nearly 28% decline over the past year for the $3.29 billion market cap company. Despite this, an InvestingPro analysis indicates the stock is undervalued with a Fair Value of $17.98. The biopharmaceutical company recently reported strong Q4 2025 financial results, including an 18% revenue increase to $139.2 million and a 57% surge in adjusted net income to $52.6 million, suggesting potential for recovery.
(ADMA) Volatility Zones as Tactical Triggers
The article provides a detailed analysis of Adma Biologics Inc (NASDAQ: ADMA) using AI-generated signals, highlighting weak sentiment across all horizons and a significant risk-reward setup. It outlines three distinct trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, tailored for different risk profiles. The analysis also includes multi-timeframe signal assessments and real-time signal access options for users.
